Hematopoietic growth factors: ESMO recommendations for the applications.

Greil, R; Psenak, O; Roila, F; ANN ONCOL. 2008; 19 Suppl 2: ii116-ii118.

The potential risk of neoadjuvant chemotherapy in breast cancer patients–results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07).

Taucher, S; Steger, GG; Jakesz, R; Tausch, C; Wette, V; Schippinger, W; Kwasny, W; Reiner, G; Greil, R; Dubsky, P; Poestlberger, S; Tschmelitsch, J; Samonigg, H; Gnant, M; Breast Cancer Res Treat. 2008; 112(2):309-316

Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy.

Dubsky, P; Sevelda, P; Jakesz, R; Hausmaninger, H; Samonigg, H; Seifert, M; Denison, U; Mlineritsch, B; Steger, G; Kwasny, W; Stöger, H; Bartsch, R; Stierer, M; Taucher, S; Fridrik, M; Schippinger, W; Greil, R; Pötter, R; Gnant, M; Clin Cancer Res. 2008; 14(7):2082-2087

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.

Gnant, M; Mlineritsch, B; Luschin-Ebengreuth, G; Kainberger, F; Kässmann, H; Piswanger-Sölkner, JC; Seifert, M; Ploner, F; Menzel, C; Dubsky, P; Fitzal, F; Bjelic-Radisic, V; Steger, G; Greil, R; Marth, C; Kubista, E; Samonigg, H; Wohlmuth, P; Mittlböck, M; Jakesz, R; Lancet Oncol. 2008; 9(9):840-849

Bim and Bmf in tissue homeostasis and malignant disease.

Piñon, JD; Labi, V; Egle, A; Villunger, A; Oncogene. 2008; 27 Suppl 1:S41-S52

Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platform

Valent, P; Lion, T; Wolf, D; Sillaber, C; Agis, H; Petzer, A; Lang, A; Kalhs, P; Geissler, D; Greil, R; Linkesch, W; Burgstaller, S; Thaler, J; Gastl, G WIEN KLIN WOCHENSCHR. 2008; 120(21-22): 697-709.

Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition.

Fischer, H; Taylor, N; Allerstorfer, S; Grusch, M; Sonvilla, G; Holzmann, K; Setinek, U; Elbling, L; Cantonati, H; Grasl-Kraupp, B; Gauglhofer, C; Marian, B; Micksche, M; Berger, W; MOL CANCER THER. 2008; 7(10): 3408-3419.

A crosstalk between intracellular CXCR7 and CXCR4 involved in rapid CXCL12-triggered integrin activation but not in chemokine-triggered motility of human T lymphocytes and CD34+ cells.

Hartmann, TN; Grabovsky, V; Pasvolsky, R; Shulman, Z; Buss, EC; Spiegel, A; Nagler, A; Lapidot, T; Thelen, M; Alon, R; J LEUKOCYTE BIOL. 2008; 84(4): 113-140.

Chemotherapy in gastric cancer.

Wöll, E; Devries, A; Eisterer, W; Hejna, M; Keil, F; Stein, H; Zacherl, J; Greil, R; Anticancer Res. 2008; 28(2B):1213-1219

Tumour-immune cell interactions modulated by chemokines.

Jöhrer, K; Pleyer, L; Olivier, A; Maizner, E; Zelle-Rieser, C; Greil, R; EXPERT OPIN BIOL TH. 2008; 8(3): 26-90.